Andere Sprachen Faron Pharmaceuticals Oy

Aktien

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:10 28.05.2024			% 5 Tage	% 1. Jan.
180 ^GBX	-6,49 %		-24,37 %	-40,98 %

20.05.	Faron Pharmaceuticals' Blutkrebs-Kombination zeigt Wirksamkeit in Mid-Stage-Studie	MT
20.05.	Faron Pharma feiert positive Ergebnisse in laufender MDS-Studie	AN

Faron Pharmaceuticals Oy - Issuance of warrants	20.05.
Faron Pharmaceuticals’ Blood Cancer Combo Shows Efficacy in Mid-stage Study	20.05.
Faron Pharma celebrates positive read-out in ongoing MDS trial	20.05.
Initial positive data from Phase 2 of BEXMAB	20.05.
Faron Pharmaceuticals Ltd. Provides First Data from Phase 2 of BEXMAB	20.05.
Issuance of warrants	17.05.
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024	16.05.
Founders named European Inventor Award finalists	16.05.
Replacement - Board Change	13.05.
Faron Pharmaceuticals' new CEO Dr Juho Jalkanen sets bold vision for 2024	08.05.
Kelso raises stake in NCC; Transense joins project	03.05.
Update on financial status	30.04.
Board Change	30.04.
Faron Pharmaceuticals Ltd. Announces Appointment of Dr. Juho Jalkanen as Director	30.04.
Faron Pharmaceuticals Oy Announces Chief Executive Officer Changes	30.04.
Faron Pharmaceuticals Oy - Insider Information, Appointment of Chief Financial Officer	16.04.
Faron confirms plans under new leadership	16.04.
Faron Confirms Plans for the Coming Months Under New Leadership	16.04.
Faron Pharmaceuticals Oy Confirms Plans for the Coming Months	16.04.
Faron Pharmaceuticals reappoints former finance chief on interim basis	15.04.

Keine Ergebnisse zu dieser Suche